Is Cobenfy an injectable or an oral tablet, and is it taken once daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cobenfy Formulation and Dosing Schedule

Cobenfy is an oral capsule taken twice daily, not an injectable medication. 1

Formulation Details

Cobenfy is available as oral capsules in three strengths 1:

  • 50 mg/20 mg (xanomeline/trospium chloride) - Buff capsules
  • 100 mg/20 mg (xanomeline/trospium chloride) - Brown capsules
  • 125 mg/30 mg (xanomeline/trospium chloride) - Swedish Orange capsules

Dosing Frequency

The medication must be taken twice daily (every 12 hours), not once daily. This is a critical distinction from some other psychiatric medications 1.

Standard Adult Dosing Schedule:

  • Days 1-2: Start with 50 mg/20 mg orally twice daily
  • Days 3-7: Increase to 100 mg/20 mg orally twice daily
  • Day 8 onward: May increase to 125 mg/30 mg orally twice daily based on tolerability
  • Maximum dose: 125 mg/30 mg twice daily 1

Important Administration Requirements:

Cobenfy must be taken either at least 1 hour before meals OR at least 2 hours after meals - food significantly affects absorption 1. The capsules should not be opened 1.

Special Population Considerations:

For geriatric patients, the dosing differs 1:

  • Start at 50 mg/20 mg twice daily
  • Use slower titration
  • Maximum dose is 100 mg/20 mg twice daily (lower than standard adult maximum)

The twice-daily oral formulation distinguishes Cobenfy from long-acting injectable antipsychotics, requiring consistent adherence to the dosing schedule for therapeutic effect 2, 3.

References

Research

Xanomeline-trospium (CobenfyTM) for Schizophrenia: A Review of the Literature.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.